Limits...
Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals.

Areberg J, Petersen KB, Chen G, Naik H - Basic Clin. Pharmacol. Toxicol. (2014)

Bottom Line: The objective was to describe the pharmacokinetics of vortioxetine and evaluate the effect of intrinsic and extrinsic factors in the healthy population.The final model was found to be reliable, stable and predictive.A reliable, stable and predictive pharmacokinetic model was developed to characterise pharmacokinetics of vortioxetine in the healthy population.

View Article: PubMed Central - PubMed

Affiliation: Division of Clinical and Quantitative Pharmacology, H. Lundbeck A/S, Valby, Denmark.

Show MeSH
Visual predictive check (VPC) plot for the final population pharmacokinetic model for vortioxetine in healthy individuals. Dose-normalised observed data (dots) and median, 2.5% and 97.5% percentiles for simulated data (solid lines) and dose-normalised observed data (dotted lines) are shown. The insert shows the first 20 hr after dosing.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4257570&req=5

fig05: Visual predictive check (VPC) plot for the final population pharmacokinetic model for vortioxetine in healthy individuals. Dose-normalised observed data (dots) and median, 2.5% and 97.5% percentiles for simulated data (solid lines) and dose-normalised observed data (dotted lines) are shown. The insert shows the first 20 hr after dosing.

Mentions: The eta shrinkages for the final model were 22% (ka), 16% (V2/F) and 2% (CL/F). Epsilon shrinkage was 4%. According to the rule-of-thumb of 20–30% 12, a small degree of shrinkage was only found for ka. The VPC plot (fig. 5) showed that the observed values lay within the 95% confidence intervals. The estimated NPDE values followed an N(0,1) distribution.


Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals.

Areberg J, Petersen KB, Chen G, Naik H - Basic Clin. Pharmacol. Toxicol. (2014)

Visual predictive check (VPC) plot for the final population pharmacokinetic model for vortioxetine in healthy individuals. Dose-normalised observed data (dots) and median, 2.5% and 97.5% percentiles for simulated data (solid lines) and dose-normalised observed data (dotted lines) are shown. The insert shows the first 20 hr after dosing.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4257570&req=5

fig05: Visual predictive check (VPC) plot for the final population pharmacokinetic model for vortioxetine in healthy individuals. Dose-normalised observed data (dots) and median, 2.5% and 97.5% percentiles for simulated data (solid lines) and dose-normalised observed data (dotted lines) are shown. The insert shows the first 20 hr after dosing.
Mentions: The eta shrinkages for the final model were 22% (ka), 16% (V2/F) and 2% (CL/F). Epsilon shrinkage was 4%. According to the rule-of-thumb of 20–30% 12, a small degree of shrinkage was only found for ka. The VPC plot (fig. 5) showed that the observed values lay within the 95% confidence intervals. The estimated NPDE values followed an N(0,1) distribution.

Bottom Line: The objective was to describe the pharmacokinetics of vortioxetine and evaluate the effect of intrinsic and extrinsic factors in the healthy population.The final model was found to be reliable, stable and predictive.A reliable, stable and predictive pharmacokinetic model was developed to characterise pharmacokinetics of vortioxetine in the healthy population.

View Article: PubMed Central - PubMed

Affiliation: Division of Clinical and Quantitative Pharmacology, H. Lundbeck A/S, Valby, Denmark.

Show MeSH